ONCE DAILY REGIMEN OF DIDANOSINE, TENOFOVIR AND EFAVIRENZ

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究的主要目的是：(1)确定艾滋病毒感染如何在身体的各个部位（包括血液、精液、阴道分泌物和脊髓液）发展，以及身体对新感染的反应；(2)了解新感染艾滋病毒的人每天服用一次抗逆转录病毒联合治疗的安全性和耐受性，并了解这种治疗在多大程度上限制了对免疫系统的损害。(3)确定新感染者中耐药病毒的频率，以及它们如何以及是否影响对治疗的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purposes of the study are (1) to determine how HIV infection develops at various sites in the body (including blood, semen, vaginal secretions and spinal fluid) and how the body responds to new infection, (2) to find out how safe and well tolerated once a day dosing of combination antiretroviral treatment is for new HIV infected persons, and to see how well this treatment limits the damage to teh immune system, and (3) to determine the frequency of resistant viruses in newly infected persons and how and if they affect response to treatment.